Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 05, 2022

SELL
$29.67 - $60.28 $2,670 - $5,425
-90 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$59.27 - $95.73 $5,334 - $8,615
90 New
90 $5,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $215M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Smith Group Asset Management, LLC Portfolio

Follow Smith Group Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Group Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Smith Group Asset Management, LLC with notifications on news.